Nektar Therapeutics

NASDAQ:NKTR

Biotechnology

Healthcare
$34.42 -2.04%

-$1.24 today

Market cap
$987.44M
Beta
1.15
P/E (TTM)
-9.3
EPS (TTM)
-$6.39
52W Low $8.27High $109.00

Volume 0.71M

Average 1.00M

NKTR Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Nektar TherapeuticsNASDAQ: NKTR

Gross Profit · Q2 FY2026 · quarter ended Jun 2026

Gross profit declines year over year

Q2 FY2026 gross profit of $10.13M fell 9.3% year over year, ahead of the -13.2% change in trailing-twelve-month gross profit. Sequentially, it fell 5.4% from the prior quarter. Over 3 fiscal years it compounded at -7.8% a year.

Context

  • Gross profit amounted to 100.0% of revenue in FY2025, up 31.2 pp from a year earlier.
  • Gross profit increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -9.3% holds above the trailing-twelve-month pace of -13.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$10.13M-5.4% QoQ
Last fiscal yearDec 2025
$55.23M-18.5% YoY
LTMJun 2026
$54.24M-13.2% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-9.3%——
1 year-18.5%——
3-year CAGR-7.8%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
55.23M USD
Year-over-year change
-18.5%
4-year CAGR
-8.0%

Gross Profit vs competitors

How NKTR compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -13.2% is the 4th highest of 9, against a peer median of -56.4%.
  • Gross profit amounts to 99.4% of revenue for NKTR, versus a peer median of 94.0%.
NKTR Competitors
Gross Profit for NKTR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMCRImmunocore Holdings plcLTM Mar 2026$381.15M USD+15.4%+28.0%98.8%
RCUSArcus Biosciences, Inc.LTM Jun 2026$110M USD-58.0%+28.4%94.0%
MGNXMacroGenics, Inc.LTM Mar 2026$109.85M USD+16.2%-9.3%69.9%
CGENCompugen Ltd.LTM Mar 2026$63.98M USD+230.5%+113.5%88.1%
NKTRNektar TherapeuticsLTM Jun 2026$54.24M USD-13.2%-7.8%99.4%
XNCRXencor, Inc.LTM Jun 2026$45.46M USD-54.8%—43.3%
IMTXImmatics N.V.LTM Mar 2026€37.3M EUR-74.1%-9.9%100.0%
CHRSCoherus Oncology, Inc.LTM Mar 2026$28.15M USD-74.3%-44.2%60.0%
ANLAdlai Nortye Ltd.LTM Jun 2024$6.49M USD——100.0%
IPHAInnate Pharma S.A.FY2025€2.79M EUR-77.9%-22.6%100.0%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026-$55K USD———
Peer median (excluding NKTR) —-56.4%-9.3%94.0%

Competitors are the stored peer set for NKTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue101.91M92.06M90.12M98.43M55.23M
Cost of Revenue24.9M21.64M36.64M30.69M0
Gross Profit77.01M70.42M53.48M67.74M55.23M
Gross Margin75.6%76.5%59.3%68.8%100.0%
Research & Development400.27M218.32M114.16M120.91M117.33M
Selling, General & Admin122.84M92.33M77.42M76.75M68.67M
Operating Expenses523.11M310.66M190.9M172.94M186M
Depreciation & Amortization14.15M12.2M7.82M4.39M1.03M
EBITDA(461.82M)(323.87M)(243.11M)(86.7M)(137M)
EBITDA Margin-453.2%-351.8%-269.8%-88.1%-248.1%
Operating Income(446.1M)(240.24M)(137.43M)(105.2M)(130.77M)
Operating Margin-437.8%-261.0%-152.5%-106.9%-236.8%
Interest Income2.73M6.78M19.01M14.5M10.44M
Interest Expense47.31M28.91M25.33M28.11M26.18M
Other Income / Expenses(77.18M)(124.75M)(138.83M)(14M)(33.44M)
Income Before Tax(523.28M)(364.98M)(276.26M)(119.2M)(164.21M)
Pre-Tax Margin-513.5%-396.5%-306.5%-121.1%-297.3%
Income Tax Expense557K3.22M(200K)(239K)(138K)
Net Income(523.84M)(368.2M)(276.06M)(118.96M)(164.08M)
Net Margin-514.0%-400.0%-306.3%-120.9%-297.1%
EPS (Basic)(42.90)(29.51)(21.79)(8.68)(9.73)
EPS (Diluted)(42.90)(29.51)(21.79)(8.68)(9.73)
Weighted Avg Shares12.22M12.48M12.67M13.71M16.87M
Weighted Avg Shares (Diluted)12.22M12.48M12.67M13.71M16.87M

Nektar Therapeutics

NASDAQ:NKTR

Intrinsic Alpha fair value

Locked

Current Price

$34.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.